Our recent study showed that A1, a novel fluorinated CXCR4 inhibitor, can effectively treat colorectal cancer (CRC) in vitro and in vivo (Khorramdelazad et al., 2023). The gene discussed is CXCR4; the disease is colorectal carcinoma.